Taysha Gene Therapies, Inc.
TSHANASDAQHealthcare● Active
$5.43
$-0.07(-1.27%)
Market Cap$1.4B
P/E Ratio—
52W High$7.3
52W Low$2.25
Taysha Gene Therapies, Inc. (TSHA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TSHA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $2.49M | $0.00M |
| Gross Profit | $9.77M | $8.33M | $15.45M | $0.01M | $0.00M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 0.60% | — |
| Operating Expenses | |||||
| R&D Expenses | $86.40M | $66.00M | $56.78M | $91.17M | $131.94M |
| G&A Expenses | $33.87M | $28.95M | $30.05M | $0.00M | $41.32M |
| Total Operating Expenses | $120.27M | $99.79M | $87.89M | $126.04M | $173.27M |
| Operating Income | ($110.50M) | ($91.46M) | ($72.44M) | ($126.03M) | ($173.27M) |
| Operating Margin %(computed) | — | — | -468.83% | — | — |
| Interest Income | $9.22M | $6.94M | $3.57M | $0.25M | $0.17M |
| Interest Expense | $0.06M | $0.10M | $5.00M | $3.80M | $1.43M |
| Income Before Tax | ($109.00M) | ($89.30M) | ($111.57M) | ($166.01M) | ($174.52M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($109.00M) | ($89.30M) | ($111.57M) | ($166.01M) | ($174.52M) |
| Net Margin %(computed) | — | — | -722.06% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
| Wtd Avg Shares | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M |
| EBITDA | ($107.79M) | ($87.95M) | ($105.20M) | ($159.73M) | ($172.60M) |
| EBITDA Margin %(computed) | — | — | -680.84% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Taysha Gene Therapies, Inc. data
About Taysha Gene Therapies, Inc. (TSHA) Income Statement
Taysha Gene Therapies, Inc. (TSHA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TSHA reported revenue of $0.01B, gross profit of $0.01B (gross margin 100.00%), and net income of ($0.11B) — a net profit margin of -1115.27%.
Frequently asked questions
TSHA · 4 questionsTaysha Gene Therapies, Inc. (TSHA) reported revenue of $0.01B for 2025, up 17.3% year-over-year.
TSHA revenueTSHA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08